Observation on the preliminary efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer
Objective To evaluate the efficacy of neoadjuvant programmed receptor 1(PD-1)monoclonal antibody immunotherapy combined with chemotherapy for non-small cell lung cancer(NSCLC).Methods This study included 176 patients with stage ⅠB～Ⅲresectable NSCLC who received neoadjuvant immunotherapy combined with chemotherapy at our research center from January 2021 to December 2023.Totally,159 patients(90.34%)received surgical treatment,including 42 cases of adenocarcinoma and 115 cases of squamous cell carcinoma.Results The median number of neoadjuvant treatment cycles was 2,with 4 patients(2.5%)achieving complete response(CR),115 patients(72.3%)achieving partial response(PR),and 40 patients(25.2%)assessed as stable disease(SD)with only 2 cases of tumor enlargement;After surgery,96 patients(60.4%,95%CI:52.7%-68.1%)achieved major pathological response(MPR),and 74 patients(46.5%,95%CI:38.7%-54.4%)achieved pathological complete response(pCR);Multivariate analysis showed that gender and programmed ligand 1(PD-L1)significantly influenced the rates of MPR and pCR.Conclusion Neoadjuvant immunotherapy combined with chemotherapy showed initial efficacy in resectable stage ⅠB～Ⅲ NSCLC,and the expression level of PD-L1 may be a predictive factor for MPR and pCR.
NETL
NSTL
万方数据
